Tests nivolumab with chemotherapy as first treatment for advanced Hodgkin lymphoma
Tests nivolumab added to chemotherapy in adults with advanced Hodgkin lymphoma.
Plain-language title generated from the registry record
Registry title: PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma
Key facts
- Where
- Moscow, RussiaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT07209059, who can take part
Where in Russia
- National Medical Research Center for HematologyMoscow, RussiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Research Center for Hematology, Russia
- Trial code
- NCT07209059
- Record updated
- 6 October 2025
- Original description
This is a single-center, open-label, phase 2 pilot study evaluating the efficacy and safety of a response-adapted first-line treatment strategy for patients with classical Hodgkin lymphoma (cHL) and unfavorable prognostic factors. The FINISH protocol (First-line Immuno-chemotherapy Navigated by Interim PET for Stratification and Hazard minimization In Hodgkin lymphoma) integrates nivolumab into induction therapy and tailors subsequent treatment based on interim PET-CT response. The study also includes exploratory monitoring of circulating tumor DNA (ctDNA) to investigate its role in early response assessment and residual disease detection.Read full original descriptionShow less
A Single-Center Pilot Study Evaluating the Efficacy and Safety of First-Line Immunochemotherapy With Nivolumab Guided by Interim PET for Stratification and Hazard Minimization in Patients With Advanced Classical Hodgkin Lymphoma (FINISH-HL)
This is a single-center, open-label, phase 2 pilot study evaluating the efficacy and safety of a response-adapted first-line treatment strategy for patients with classical Hodgkin lymphoma (cHL) and unfavorable prognostic factors. The FINISH protocol (First-line Immuno-chemotherapy Navigated by Interim PET for Stratification and Hazard minimization In Hodgkin lymphoma) integrates nivolumab into induction therapy and tailors subsequent treatment based on interim PET-CT response. The study also includes exploratory monitoring of circulating tumor DNA (ctDNA) to investigate its role in early response assessment and residual disease detection.
Inclusion: Signed written informed consent prior to any study-specific procedures; Histologically confirmed classical Hodgkin lymphoma (cHL); Newly diagnosed disease, Ann Arbor stage IIB (bulky), III, or IV; At least one measurable lesion ≥15 mm in the longest diameter (by CT); Age between 18 and 60 years (inclusive); ECOG performance status 0-2; PET-CT performed at baseline; No prior chemotherapy, radiotherapy, or immunotherapy for lymphoma; Adequate organ function, including:; Serum creatinine ≤ 0.2 mmol/L; Absence of severe cardiac, pulmonary, hepatic, or renal dysfunction; Ability to comply with the study protocol and scheduled visits.
Exclusion: Prior or active autoimmune disease requiring systemic therapy; Vaccination with a live vaccine within 30 days prior to first nivolumab dose; Active hepatitis B or C infection; Positive test for HIV; History of non-infectious pneumonitis requiring corticosteroids; Prior malignancy (except for adequately treated basal cell carcinoma or cervical carcinoma in situ); Congestive heart failure, unstable angina, recent myocardial infarction, or severe cardiac arrhythmias; Severe pneumonia with respiratory failure or hypoxemia not corrected within 2-3 days; Life-threatening bleeding events (e.g., gastrointestinal or cerebral hemorrhage); Decompensated diabetes mellitus; Any somatic or psychiatric condition that, in the investigator's judgment, precludes informed consent or study participation; Severe renal impairment (serum creatinine > 0.2 mmol/L), unless lymphoma-related; Cachexia (total serum protein < 35 g/L), unless due to lymphoma-related liver damage; Pregnancy or breastfeeding; Severe hepatic dysfunction, unless directly related to lymphoma; Sepsis or hemodynamic instability.